NATIONAL HARBOR, Md.—An investigational iron-based phosphate binder is effective and well tolerated in hemodialysis (HD) patients with hyperphosphatemia, according to data presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Dialysis patient underreporting of noncompliance with phosphate binder therapy may contribute to poor phosphorus control, investigators reported at the National Kidney Foundation 2012 Spring Clinical Meetings.
